Downsizing a human inflammatory protein to a small molecule with equal potency and functionality

Nature Communications

Volumn 4, Issue , 2013, Pages

  Reid, Robert C ^a   Yau, Mei Kwan ^a   Singh, Ranee ^a   Hamidon, Johan K ^a   Reed, Anthony N ^a   Chu, Peifei ^a   Suen, Jacky Y ^a   Stoermer, Martin J ^a   Blakeney, Jade S ^a   Lim, Junxian ^a   Faber, Jonathan M ^a   Fairlie, David P ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; COMPLEMENT COMPONENT C3A; PEPTIDE;

BIOAVAILABILITY; HYDROGEN; IMMUNE SYSTEM; MOLECULAR ANALYSIS; PLASMA; PROTEIN; STABILIZATION;

AGONIST; ARTICLE; ATOM; BINDING AFFINITY; BIOAVAILABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYDROGEN BOND; INNATE IMMUNITY; MOLECULAR WEIGHT; PROTEIN INTERACTION; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

COMPLEMENT C3A; HUMANS; INFLAMMATION MEDIATORS; RECEPTORS, COMPLEMENT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84888224815     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3802     Document Type: Article

References (47)

1. DeGrado, W. F., Summa, C. M., Pavone, V., Nastri, F. & Lombardi, A. De novo design and structural characterization of proteins and metalloproteins. Annu. Rev. Biochem. 68, 779-819 (1999).
2. Stigers, K. D., Soth, M. J. & Nowick, J. S. Designed molecules that fold to mimic protein secondary structures. Curr. Opin. Chem. Biol. 3, 714-723 (1999).
3. Venkatraman, J., Shankaramma, S. C. & Balaram, P. Design of folded peptides. Chem. Rev. 101, 3131-3152 (2001).
4. Tyndall, J. D. A., Pfeiffer, B., Abbenante, G. & Fairlie, D. P. Over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure. Chem. Rev. 105, 793-826 (2005).
5. Seebach, D. & Gardiner, J. Beta-peptidic peptidomimetics. Acc. Chem. Res. 41, 1366-1375 (2008).
6. Yin, H. & Hamilton, A. D. Strategies for targeting protein-protein interactions with synthetic agents. Angew. Chem. Int. Ed. 44, 4130-4163 (2005).
7. Fairlie, D. P., West, M. L. & Wong, A. K. Towards protein surface mimetics. Curr. Med. Chem. 5, 29-62 (1998).
8. Bullock, B. N., Jochim, A. L. & Arora, P. S. Assessing helical protein interfaces for inhibitor design. J. Am. Chem. Soc. 133, 14220-14223 (2011).
9. Scholtz, J. M. & Baldwin, R. L. The mechanism of alpha-helix formation by peptides. Annu. Rev. Biophys. Biomol. Struct. 21, 95-118 (1992).
10. Gerard, N. P. & Gerard, C. Complement in allergy and asthma. Curr. Opin. Immunol. 14, 705-708 (2002).
11. Haas, P.-J. & van, S. J. Anaphylatoxins: Their role in bacterial infection and inflammation. Immunol. Res. 37, 161-175 (2007).
12. Hugli, T. E. Structure and function of the anaphylatoxins. Springer Semin. Immunopathol. 7, 193-219 (1984).
13. Masters, S. L., Simon, A., Aksentijevich, I. & Kastner, D. L. Horror autoinflammaticus: The molecular pathophysiology of autoinflammatory disease. Annu. Rev. Immunol. 27, 621-668 (2009).
14. Zipfel, P. F. & Skerka, C. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 9, 729-740 (2009).
15. Mizutani, N., Nabe, T. & Yoshino, S. Complement C3a regulates late asthmatic response and airway hyperresponsiveness in mice. J. Immunol. 183, 4039-4046 (2009).
16. Hutamekalin, P. et al. Effect of the C3a-receptor antagonist SB 290157 on anti-OVA polyclonal antibody-induced arthritis. J. Pharmacol. Sci. 112, 56-63 (2010).
17. Kildsgaard, J. et al. Cutting edge: Targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxinshock. J. Immunol. 165, 5406-5409 (2000).
18. Jacob, A., Bao, L., Brorson, J., Quigg, R. J. & Alexander, J. J. C3aR inhibition reduces neurodegeneration in experimental lupus. Lupus 19, 73-82 (2010).
19. Mamane, Y. et al. The C3a anaphylatoxin receptor is a key mediator of insulin resistance and functions by modulating adipose tissue macrophage infiltration and activation. Diabetes 58, 2006-2017 (2009).
20. Takematsu, H., Ohkohchi, K. & Tagami, H. Demonstration of anaphylatoxins C3a, C4a and C5a in the scales of psoriasis and inflammatory pustular dermatoses. Br. J. Dermatol. 114, 1-6 (1986).
21. Tang, Z., Lu, B., Hatch, E., Sacks, S. H. & Sheerin, N. S. C3a mediates epithelialto-mesenchymal transition in proteinuric nephropathy. J. Am. Soc. Nephrol. 20, 593-603 (2009).
22. Proctor, L. M. et al. Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury. Br. J. Pharmacol. 142, 756-764 (2004).
23. Lim, J. et al. C5aR and C3aR antagonists each inhibit diet-induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling. FASEB J. 27, 822-831 (2013).
24. Pasupuleti, M. et al. Preservation of antimicrobial properties of complement peptide C3a, from invertebrates to humans. J. Biol. Chem. 282, 2520-2528 (2007).
25. Sonesson, A. et al. Antifungal activity of C3a and C3a-derived peptides against Candida. Biochim. Biophys. Acta Biomembr. 1768, 346-353 (2007).
26. Bokisch, V. A. & Mullereb, H. j. Anaphylatoxin inactivator of human plasma-its isolation and characterization as a carboxypeptidase. J. Clin. Invest. 49, 2427-2436 (1970).
27. Wilken, H.-C., Gotze, O., Werfel, T. & Zwirner, J. C3a(desArg) does not bind to and signal through the human C3a receptor. Immunol. Lett. 67, 141-145 (1999).
28. Scully, C. C. et al. Selective hexapeptide agonists and antagonists for human complement C3a receptor. J. Med. Chem. 53, 4938-4948 erratum 8208 (2010).
29. Ames, R. S. et al. Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models. J. Immunol. 166, 6341-6348 (2001).
30. Denonne, F. et al. Discovery of new C3aR ligands. Part 2: Amino-piperidine derivatives. Bioorg. Med. Chem. Lett. 17, 3262-3265 (2007).
31. Denonne, F. et al. Discovery of new C3aR ligands. Part 1: Arginine derivatives. Bioorg. Med. Chem. Lett. 17, 3258-3261 (2007).
32. Grant, E. B. et al. Design, synthesis, and biological activity of diiminoisoindolines as complement component 3a antagonists. Bioorg. Med. Chem. Lett. 11, 2817-2820 (2001).
33. Ghassemian, A. et al. Efficient chemical synthesis of human complement protein C3a. Chem. Commun. 49, 2356-2358 (2013).
34. Bajic, G., Yatime, L., Klos, A. & Andersen, G. R. Human C3a and C3a desArg anaphylatoxins have conserved structures, in contrast to C5a and C5a desArg. Protein Sci. 22, 204-212 (2013).
35. Huber, R., Scholze, H., Paques, E. P. & Deisenhofer, J. Crystal structure analysis and molecular model of human C3a anaphylatoxin. Hoppe Seylers Z. Physiol. Chem. 361, 1389-1399 (1980).
36. Hugli, T. E. & Erickson, B. W. Synthetic peptides with the biological activities and specificity of human C3a anaphylatoxin. Proc. Natl Acad. Sci. USA 74, 1826-1830 (1977).
37. Ember, J. A. & Hugli, T. E. Complement factors and their receptors. Immunopharmacology 38, 3-15 (1997).
38. Chao, T. H. et al. Role of the second extracellular loop of human C3a receptor in agonist binding and receptor function. J. Biol. Chem. 274, 9721-9728 (1999).
39. Fukuoka, Y., Ember, J. A. & Hugli, T. E. Ligand binding sites on guinea pig C3aR: Point and deletion mutations in the large extracellular loop and vicinity. Biochem. Biophys. Res. Commun. 263, 357-360 (1999).
40. Sun, J. Z. et al. Identification of ligand effector binding sites in transmembrane regions of the human G protein-coupled C3a receptor. Protein Sci. 8, 2304-2311 (1999).
41. Wu, B. L. et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 1066-1071 (2010).
42. Ruiz-Gomez, G., Tyndall, J. D. A., Pfeiffer, B., Abbenante, G. & Fairlie, D. P. Update 1 of: Over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure. Chem. Rev. 110, PR1-PR41 (2010).
43. Frisch, M. J. et al. Gaussian 09, Revision A.02 (Gaussian Inc., Wallingford, CT, 2009).
44. Munkonda, M. N. et al. Recombinant acylation stimulating protein administration to C3(-/-) mice increases insulin resistance via adipocyte inflammatory mechanisms. PLoS One 7, e46883 (2012).
45. Dreier, L. & Wider, G. Concentration measurements by PULCON using X-filtered or 2D NMR spectra. Magn. Reson. Chem. 44, S206-S212 (2006).
46. Kirshenbaum, A. S. et al. Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Leuk. Res. 27, 677-682 (2003).
47. Kuehn, H. S., Radinger, M. & Gilfillan, A. M. Current Protocols in Immunology. (eds John, E. C. et al.) (Chapter 7, Unit 7, 38, 2010).